INDV
Indivior PLC
$
29.370
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
30.260
Open
29.680
VWAP
29.36
Vol
3.59M
Mkt Cap
3.67B
Low
28.760
Amount
105.47M
EV/EBITDA(TTM)
--
Total Shares
134.08M
EV
3.54B
EV/OCF(TTM)
--
P/S(TTM)
3.17
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
298.42M
+0.14%
0.557
+74.82%
263.20M
-1.05%
0.495
+20.73%
276.00M
-8.61%
0.570
+11.76%
Estimates Revision
The market is revising Upward the revenue expectations for Indivior PLC (INDV) for FY2025, with the revenue forecasts being adjusted by 0.13% over the past three months. During the same period, the stock price has changed by 38.41%.
Revenue Estimates for FY2025
Revise Upward
+0.13%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+2.25%
In Past 3 Month
Stock Price
Go Up
+38.41%
In Past 3 Month
7 Analyst Rating
607.73% Upside
Wall Street analysts forecast INDV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDV is 207.86 USD with a low forecast of 20.00 USD and a high forecast of 1288 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
607.73% Upside
Current: 29.370
Low
20.00
Averages
207.86
High
1288
607.73% Upside
Current: 29.370
Low
20.00
Averages
207.86
High
1288
Northland
Outperform
upgrade
$30 -> $40
2025-10-31
New
Reason
Northland
Price Target
$30 -> $40
2025-10-31
New
upgrade
Outperform
Reason
Northland raised the firm's price target on Indivior to $40 from $30 and keeps an Outperform rating on the shares. The firm's upward revision reflects confidence in Sublocade's prospects, combined with Indivior's cost containment initiatives, the analyst tells investors.
Craig-Hallum
Buy
maintain
$34 -> $41
2025-10-31
New
Reason
Craig-Hallum
Price Target
$34 -> $41
2025-10-31
New
maintain
Buy
Reason
Craig-Hallum raised the firm's price target on Indivior to $41 from $34 and keeps a Buy rating on the shares. The firm cites the company's Q3 massive beat, delivering revenue of $314M, beating Street estimates of $261.9M, with broad-based strength from both Sublocade and Suboxone.
Piper Sandler
NULL -> Overweight
upgrade
$27 -> $41
2025-10-31
New
Reason
Piper Sandler
Price Target
$27 -> $41
2025-10-31
New
upgrade
NULL -> Overweight
Reason
Piper Sandler raised the firm's price target on Indivior to $41 from $27 and keeps an Overweight rating on the shares. The firm notes Indivior reported Q3 2025 diluted non-GAAP earnings per share of 72c on revenue of $314M, compared to Street estimates of 41c and $262M, respectively. Management is now guiding to Sublocade worldwide sales of $825M-$845M, up from the previous range of $765M-$785M, and now implying annual growth of about 10% at the midpoint.
H.C. Wainwright
Brandon Folkes
maintain
$28 -> $35
2025-10-30
New
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$28 -> $35
2025-10-30
New
maintain
Reason
H.C. Wainwright analyst Brandon Folkes raised the firm's price target on Indivior to $35 from $28 and keeps a Buy rating on the shares. The company reported a strong Q3 that exceeded expectations across all key metrics and validated the firm's positive call on the stock into the quarter, the analyst tells investors in a research note. The firm added that its revised target may still prove conservative, as it implies just 7.4x 2026 EV/EBITDA, compared to the peer group average of about 9.8x, suggesting meaningful re-rating potential as execution continues.
H.C. Wainwright
Brandon Folkes
Buy
initiated
$27
2025-08-06
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$27
2025-08-06
initiated
Buy
Reason
H.C. Wainwright analyst Brandon Folkes initiated coverage of Indivior with a Buy rating and $27 price target. The firm sees a favorable risk/reward at current share levels, saying the durability of Sublocade revenue in the growing long-acting injectable market for opioid use disorder is underappreciated. In addition, Indivior's operational focus could drive meaningful cost reduction efforts in non-core areas of the company, the analyst tells investors in a research note.
Northland
Carl Byrnes
maintain
$22 -> $30
2025-08-01
Reason
Northland
Carl Byrnes
Price Target
$22 -> $30
2025-08-01
maintain
Reason
Northland analyst Carl Byrnes raised the firm's price target on Indivior to $30 from $22 and keeps an Outperform rating on the shares. Following "outstanding" Q2 results, the firm contends that commercial initiatives combined with cost savings support adjusted EPS of $2.00 in FY26.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Indivior PLC (INDV.O) is 10.46, compared to its 5-year average forward P/E of 12.72. For a more detailed relative valuation and DCF analysis to assess Indivior PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
12.72
Current PE
10.46
Overvalued PE
16.04
Undervalued PE
9.41
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Overvalued
5Y Average EV/EBITDA
6.42
Current EV/EBITDA
8.99
Overvalued EV/EBITDA
8.30
Undervalued EV/EBITDA
4.53
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Overvalued
5Y Average PS
2.27
Current PS
29.37
Overvalued PS
3.82
Undervalued PS
0.73
Financials
Annual
Quarterly
FY2025Q3
YoY :
+2.28%
314.00M
Total Revenue
FY2025Q3
YoY :
-53.19%
44.00M
Operating Profit
FY2025Q3
YoY :
+950.00%
42.00M
Net Income after Tax
FY2025Q3
YoY :
+1000.00%
0.33
EPS - Diluted
FY2025Q3
YoY :
+5500.00%
-56.00M
Free Cash Flow
FY2025Q3
YoY :
-8.93%
73.57
Gross Profit Margin - %
FY2025Q3
YoY :
-151.26%
11.19
FCF Margin - %
FY2025Q3
YoY :
+929.23%
13.38
Net Margin - %
FY2025Q3
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
859.9K
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
1
1.2M
Volume
Months
6-9
3
6.0M
Volume
Months
0-12
2
1.7M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
INDV News & Events
Events Timeline
2025-10-01 (ET)
2025-10-01
08:15:46
Indivior plans to relocate its headquarters from the U.K. to the U.S.
2025-07-31 (ET)
2025-07-31
07:39:36
Indivior raises 2025 revenue view to $1.03B-$1.08B from $955M-$1.025B
2025-07-31
07:37:35
Indivior reports Q2 non-GAAP EPS 51c, consensus 25c
Sign Up For More Events
Sign Up For More Events
News
4.0
10-31BenzingaPiper Sandler Maintains Overweight Rating on Indivior, Increases Price Target to $41
2.0
10-31NASDAQ.COMBiotech Stocks Reach 52-Week Peaks: MTSR, INSM, ABVX, and MAZE Drive Surge on October 30
9.5
10-30NASDAQ.COMIndivior Plc. Reports Higher Q3 Profit, Surpassing Expectations
Sign Up For More News
People Also Watch
IMCR
Immunocore Holdings PLC
33.090
USD
+2.80%
DYN
Dyne Therapeutics Inc
22.580
USD
-4.12%
HLIT
Harmonic Inc
10.700
USD
+0.47%
KSS
Kohls Corp
16.270
USD
+3.17%
SCL
Stepan Co
43.350
USD
+1.00%
UMH
UMH Properties Inc
14.540
USD
+2.25%
UTI
Universal Technical Institute Inc
29.720
USD
-9.39%
GSBD
Goldman Sachs BDC Inc
9.980
USD
+0.71%
LNN
Lindsay Corp
111.240
USD
+1.04%
SFL
SFL Corporation Ltd
7.460
USD
+3.04%
FAQ
What is Indivior PLC (INDV) stock price today?
The current price of INDV is 29.37 USD — it has increased 0.82 % in the last trading day.
What is Indivior PLC (INDV)'s business?
What is the price predicton of INDV Stock?
What is Indivior PLC (INDV)'s revenue for the last quarter?
What is Indivior PLC (INDV)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Indivior PLC (INDV)'s fundamentals?
How many employees does Indivior PLC (INDV). have?